DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT06420739

Active not recruiting

The Semaglutide Study

Improving Patient Safety for Surgical Patients on Semaglutide: A Gastric Ultrasound Initiative

Asset

Semaglutide

GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

100

actual

Study population

Perioperative / gastric aspiration risk

Key I/E criterion

—

Primary endpoint

•Full stomach

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06420739
Org study ID23-5873

Timeline

Milestones

Study start2024-03-25actual
Study first posted2024-05-20actual
Last update posted2025-11-20actual
Primary completion2025-11-30estimated
Study completion2026-03-31estimated

Assets

Investigational agents

Semaglutide

Study populations

Who this study enrolls

Perioperative / gastric aspiration risk

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted
Sampling methodNon probability sample

Study population text

A cohort of 100 patients undergoing elective surgery while under treatment with Semaglutide for either diabetes or for losing weight.

Inclusion criteria

1. Patients scheduled for elective surgery at Toronto Western Hospital

2. Aged ≥ 18 years of age

3. American Society of Anaesthesia physical status classification I to III

4. Patients being treated with Semaglutide for at least 1 month

Exclusion criteria

1. Current pregnancy evidenced by positive urinary pregnancy test

2. Previous surgery of the upper gastrointestinal tract

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Safety / tolerability / PK
2
Other clinical outcomes
1

Safety / tolerability / PK

2 endpoints
Primary/protocol endpoint

Incidence of full stomach.

Time frame:Pre-Surgical fasting duration per guideline

event count, event

Secondary/protocol endpoint

Impact of age, sex and the time since the last dose of Semaglutide, on the incidence of "full stomach".

Time frame:Pre-Surgical fasting duration per guideline

event count, event

Other clinical outcomes

1 endpoint
Secondary/protocol endpoint

Any changes in anesthetic management from the a priori plan following the result of the gastric ultrasound examination.

Time frame:Pre-operative anesthesia management plan

event count, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.